Core B: Clinical Core

摘要-核心B：临床核心 密歇根州ADRC临床核心（CC）支持和推进阿尔茨海默病及相关疾病的研究。 痴呆症（ADRD）通过招募纵向队列（LC），其深度临床和生物标志物 表征支持该中心的识别，理解和调节非 淀粉样因子导致脑功能障碍和神经变性。消委会将继续利用其 强大的区域基础设施，将LC从414个积极参与者扩大到550个参与者， 保持对有认知能力下降风险或表现出认知能力下降最早迹象的个体的关注。加大 我们通过继续运营我们在底特律成功的卫星位置（约40%的 我们的LC确定为美国黑人）和计划扩展到大急流城西班牙裔/拉丁裔 社区与数据管理和统计（DMSC）、生物标志物（BC）和 神经影像学（NIC）核心，我们将通过共享UDS加强可用的痴呆症相关研究资源 数据，生物标志物标本和神经影像扫描与国家阿尔茨海默氏症协调中心， 国家阿尔茨海默病和相关痴呆症集中储存库。CC活动指导 五个目标。目标1将促进和加强尖端临床研究。消委会将继续支持 广泛的药理学和非药理学临床试验以及观察性研究， 痴呆症谱系持续的NIA资助将提高我们在全球范围内推进ADRD研究的能力。 三所合作大学组成密歇根州ADRC。目标2将增强老龄化和痴呆症的多样性 research.我们将在底特律成功的卫星模式的基础上，向大急流城扩张 西班牙裔/拉丁裔社区。目标3将促进新型生物标志物的研究。消委会将与 DMSC、BC和NIC有助于识别和评估低成本、非侵入性的基于血液的 生物标志物，通过与由结构和生物标志物提供的A/T/N（和“V”-血管）分类进行比较， 代谢成像目标4将通过发展和完善反馈意见来加强参与者的经验。我们有 我们发现LC参与者对学习他们的临床和生物标志物结果有极大的兴趣。我们 将与外联，招募和参与核心合作，以确保生物标志物的道德披露 并酌情促进临床护理。目标5将促进下一代的培训， 痴呆症研究人员和临床医生。与研究教育部门合作，CC将 利用全面的资源和多样化的培训机会，为早期职业生涯 调查人员在三所参与大学的校园里进行了调查。总而言之，CC将关键链接 机构和区域资源，以支持多学科研究，从早期发现到 治疗干预我们对少数族裔招募、新型生物标志物和参与者反馈的重视将 支持密歇根州ADRC和更广泛的ADC网络内的研究新途径。

ABSTRACT – CORE B: CLINICAL CORE The Michigan ADRC Clinical Core (CC) supports and advances research on Alzheimer’s disease and related dementias (ADRD) through recruitment of a longitudinal cohort (LC), whose deep clinical and biomarker characterization supports the center’s central theme of identifying, understanding, and modulating the non- amyloid factors contributing to brain dysfunction and neurodegeneration. The CC will continue to draw on its robust regional infrastructure to expand the LC from 414 active participants to 550 participants, while maintaining a focus on individuals at risk for or showing the earliest signs of cognitive decline. We will intensify our commitment to diversity through continued operation of our successful satellite location in Detroit (~40% of our LC identifies as Black American) and a planned expansion to the Grand Rapids Hispanic/Latino community. In conjunction with the Data Management and Statistical (DMSC), Biomarker (BC), and Neuroimaging (NIC) Cores, we will strengthen available dementia-related research resources by sharing UDS data, biomarker specimens, and neuroimaging scans with the National Alzheimer’s Coordinating Center and the National Centralized Repository for Alzheimer’s Disease and Related Dementias. CC activities are guided by 5 aims. Aim 1 will facilitate and enhance cutting-edge clinical research. The CC will continue to support a wide range of pharmacologic and non-pharmacologic clinical trials as well as observational studies that span the dementia spectrum. Continued NIA funding will enhance our capacity to advance ADRD research at the three partner universities comprising the Michigan ADRC. Aim 2 will enhance diversity in aging and dementia research. We will build on our successful Detroit satellite model and expand into the Grand Rapids Hispanic/Latino community. Aim 3 will promote novel biomarker research. The CC will collaborate with the DMSC, BC and NIC to facilitate the identification and evaluation of low-cost, non-invasive blood-based biomarkers, through comparison to the A/T/N (and “V” – vascular) classification provided by structural and metabolic imaging. Aim 4 will enhance participant experience by developing and refining feedback. We have identified overwhelming interest among our LC participants in learning their clinical and biomarker results. We will partner with the Outreach, Recruitment, and Engagement Core to ensure ethical disclosure of biomarker findings and facilitate clinical care as appropriate. Aim 5 will facilitate the training of the next generation of dementia researchers and clinicians. Collaborating with the Research Education Component, the CC will leverage the comprehensive resources and diverse training opportunities available for early career investigators across the campuses of the three participating universities. In summary, the CC will link critical institutional and regional resources to support multi-disciplinary research, spanning from early detection to therapeutic intervention. Our emphasis on minority recruitment, novel biomarkers, and participant feedback will bolster new avenues of research within the Michigan ADRC and the broader ADC network.